๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase 2 Study of Pegylated Liposomal Doxorubicin, Vincristine, Decreased-Frequency Dexamethasone, and Thalidomide in Newly Diagnosed and Relapsed-Refractory Multiple Myeloma

โœ Scribed by Hussein, Mohamad A.; Baz, Rachid; Srkalovic, Gordan; Agrawal, Neeraj; Suppiah, Revathi; Hsi, Eric; Andresen, Steven; Karam, Mary Ann; Reed, Janice; Faiman, Beth

Book ID
123321602
Publisher
Mayo Clinic
Year
2006
Tongue
English
Weight
97 KB
Volume
81
Category
Article
ISSN
0025-6196

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A Phase II trial of pegylated liposomal
A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients
โœ Mohamad A. Hussein; Laura Wood; Eric Hsi; Gordan Srkalovic; MaryAnn Karam; Paul ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 91 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND Patients with multiple myeloma (MM) have increased bone marrow angiogenesis, a low plasma cell labeling index, and multidrug resistance (the primary cause of chemotherapy failure). MM patients receiving the vincristine, doxorubicin, and dexamethasone (VAD) regimen develop

Phase II clinical trial of arsenic triox
Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma
โœ C.C. Hofmeister; B. Jansak; N. Denlinger; E.H. Kraut; D.M. Benson; S.S. Farag ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 90 KB

In patients with multiple myeloma, there is preclinical justification to combine arsenic trioxide (ATO and As 2 O 3 ) with DVd (Doxil TM , vincristine, and dexamethasone) for newly diagnosed patients. Eleven patients on this phase II trial received 0.15 mg/kg of ATO for five consecutive days followe